Exhibit 99.1

 

 

 

CONTACT INFORMATION

 

 

Investor Relations

Contact:  

Mary Kay Ladone, Senior Vice President, Corporate Development, Strategy and Investor Relations

Contact:  

Lorna Williams, Executive Director, Investor Relations and Strategy

Phone:   312-819-9387 Phone:   312-233-7799
Email:   marykay.ladone@hillrom.com Email:   lorna.williams@hillrom.com

 

 

Media

Contact:Howard Karesh, Vice President, Corporate Communications
Phone:312-819-7268
Email:howard.karesh@hillrom.com

 

HILLROM EXCEEDS FOURTH QUARTER GUIDANCE WITH STRONG FINISH TO FISCAL YEAR

 

Company Achieves Record 2021 Financial Results While Advancing Connected CareTM

 

 

CHICAGO, November 5, 2021

– Hillrom (NYSE: HRC) today announced financial results for its fiscal fourth quarter and full-year ended September 30, 2021.

 

For the fiscal fourth quarter, Hillrom reported GAAP earnings of $0.80 per diluted share, an increase of 27 percent compared to $0.63 per diluted share in the prior-year period. On an adjusted basis, excluding special items, earnings of $1.67 per diluted share increased 43 percent and exceeded the company’s previously-issued guidance range of $1.44 to $1.48 per diluted share. Adjustments to reported earnings are detailed in the reconciliation schedules provided.

 

For fiscal 2021, Hillrom reported GAAP earnings of $3.72 per diluted share, an increase of 12 percent compared to $3.32 per diluted share for fiscal 2020. On an adjusted basis, excluding special items, adjusted earnings of $6.31 per diluted share advanced 14 percent over the prior-year period.

 

“We delivered yet another strong quarter to conclude a very successful year for Hillrom, resulting in record financial performance for fiscal 2021,” said John Groetelaars, Hillrom president and CEO. “I am very proud of the global Hillrom team for their unwavering commitment and resiliency, and the tremendous value they have created for patients, caregivers, and our shareholders as we continue to advance our vision of connected care.”

 

   
 

 

Fiscal Fourth Quarter Financial Results

 

For the fiscal fourth quarter, worldwide revenue of $798 million increased 13 percent on both a reported and constant currency basis, reflecting strong underlying performance and continued recovery across all three business segments. One-time COVID purchases contributed revenue of approximately $20 million and adjusted earnings of $0.10 per diluted share.

 

Fiscal Fourth Quarter Revenue by Reporting Segment:

 

·Patient Support Systems revenue of $417 million increased 14 percent on both a reported and constant currency basis. Excluding one-time COVID purchases in both the current and prior-year periods, Patient Support Systems revenue advanced 16 percent on a constant currency basis, reflecting robust double-digit growth across med-surg and ICU bed systems, and the company’s care communications platforms.

 

·Front Line Care generated revenue of $296 million, an increase of 14 percent on a reported basis (or 13 percent on a constant currency basis). This performance was driven by strong demand and double-digit growth for Welch Allyn patient vital signs and cardiac monitoring devices, physical assessment tools including new digital solutions, and vision screening products. Revenue also includes a one-time retrospective reimbursement benefit of $12 million for certain respiratory health devices.

 

·Surgical Solutions revenue of $85 million increased 6 percent on a reported basis (or 5 percent on a constant currency basis) with improved demand for patient positioning equipment and operating room tables, including record placements of Integrated Table Motion, as surgical procedures continued to rebound.

 

Fiscal 2021 and Recent Highlights

 

Supporting Hillrom’s strong financial performance and operational execution were significant milestones in 2021 aimed at advancing innovation, transforming the portfolio, and delivering sustainable value to shareholders. Highlights include:

 

·Achieving record revenue of $3.02 billion for fiscal 2021, an increase of 5 percent on a reported basis (or 3 percent on a constant currency basis), fueled by more than 20% growth of the company’s connected care solutions, which now comprise nearly 30 percent of Hillrom’s total revenue.

 

·Delivering $690 million in new product revenue, an increase of 20 percent compared to the prior year. Contributing to this performance were several innovative products, including the company’s portfolio of smart beds, vital signs monitoring devices, vision products, as well as Integrated Table Motion.

 

·Generating operating cash flow for the year of $476 million and delivering significant value to shareholders through increased dividends and share repurchases. During fiscal 2021, Hillrom raised its dividend for the eleventh consecutive year and returned $202 million to shareholders through dividends and share repurchases.

 

   
 

 

·Enhancing patient access to annual diabetic retinal examinations with a new commercial partnership with one of the leading retail pharmacy chains in the United States. Diabetic retinopathy is the leading cause of vision loss and blindness among adults between 20 and 74 years of age, but with early detection, 95% of diabetes-related vision loss can be prevented.

 

·Driving Hillrom’s vision of Advancing Connected Care by completing three M&A transactions including:

 

Bardy Diagnostics, Inc. (BardyDx), an innovator in digital health and a leading provider of ambulatory cardiac monitoring technologies whose differentiated Carnation Ambulatory Monitor (or CAM patch) is engineered for patient-comfort, superior P-wave clarity, exceptional diagnostic yield and superior clinical accuracy.

 

EarlySense’s contact-free continuous monitoring AI-based technology, which enhances Hillrom’s differentiated suite of connected sensing and digital communication solutions to improve patient safety and ensure timely and effective clinical intervention. Hillrom defined a new standard of care with the integration of EarlySense’s monitoring and analytics technology into the Centrella® Smart+ med-surg bed and ecosystem of connected devices.

 

Epiphany Healthcare1, extending Hillrom’s ECG management functionality into ambulatory care settings. The company offers an interoperable connectivity solution capable of supporting more than 260 unique devices from more than 80 manufacturers and integrating across all major Electronic Medical Record (EMR) vendors.

 

·Supporting local, national, and international communities with both monetary and product donations totaling more than $7.0 million, including support for critical emergency responses in India and Haiti.

 

·Promoting excellence in the workplace and commitment to diversity, inclusion and belonging initiatives as the recipient of multiple awards and recognitions. Hillrom was recently named a "Noteworthy Company" for the second year in a row as part of the DiversityInc Top 50 Companies, a designation acknowledging leadership accountability, talent programs, workplace practices, supplier diversity efforts and overall corporate philanthropy.

 

Pending Transaction with Baxter International

 

Groetelaars continued, “We remain enthusiastic about our pending combination with Baxter and are looking forward to coming together to advance our shared mission. The companies continue to make progress with integration planning and securing regulatory approvals, and we remain on track to close the transaction by early 2022.”

 

____________________________

1 Epiphany Cardiography Products, LLC and its wholly owned subsidiary Epiphany Healthcare Data Management, LLC are known as Epiphany Healthcare

 

   
 

 

As announced on September 2, 2021, Hillrom has entered into a definitive merger agreement under which Baxter has agreed to acquire Hillrom for $156.00 per share in cash. The transaction is subject to the approval of Hillrom shareholders and the satisfaction of customary closing conditions, including regulatory approvals. The waiting period under the Hart Scott Rodino Act has expired and the parties have submitted their initial filings for all required regulatory approvals, including in the European Union. Hillrom continues to expect the transaction to close by early 2022. As a result of the proposed transaction, the company is not providing financial guidance for fiscal 2022.

 

Discussion of Adjusted Financial Measures

 

In addition to the results reported in accordance with accounting principles generally accepted in the United States (GAAP), Hillrom routinely provides operating margin, income before taxes, income tax expense, and earnings per diluted share results on an adjusted basis because the company’s management believes these measures contribute to an understanding of our financial performance, provide additional analytical tools to understand our results from core operations, and reveal underlying operating trends. These measures exclude strategic developments, acquisition and integration costs and related fair value adjustments, gains and losses associated with disposals of businesses or significant product lines, regulatory costs related to updating existing product registrations to comply with the European Medical Device Regulations, special charges, changes in tax accounting methods, other tax law changes and expenses associated with these tax items, the impacts of significant litigation matters, certain impacts of the COVID-19 pandemic, and other unusual events. The company also excludes expenses associated with the amortization of purchased intangible assets. These adjustments are made to allow investors to evaluate and understand operating trends excluding their impact on operating income and earnings per diluted share.

 

Management uses these measures internally for planning, forecasting and evaluating the performance of the business. Investors should consider these non-GAAP measures in addition to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Reconciliations of GAAP measures to adjusted measures appear in the financial tables of this release.

 

The company also routinely provides earnings per diluted share guidance on an adjusted basis. This excludes the impact of intangible asset amortization associated with prior business acquisitions, which we expect to be $1.26 to $1.31 per diluted share for the fiscal year 2022. Management also does not include adjusted items such as strategic developments, acquisition and integration costs, special charges, and other special items or unusual items in our guidance because such items are evaluated on an ongoing basis, can be highly variable and cannot be reasonably predicted. As such, prospective quantification of these items is not feasible, and a full reconciliation of non-GAAP earnings per diluted share guidance to GAAP earnings per diluted share has not been provided. However, as a result of acquisitions, our ongoing portfolio and business optimization initiatives, and any change to the transitional impacts from U.S. tax reform legislation, we do expect adjusted items we have not predicted to potentially be significant to our GAAP measures including gross margin, operating margin, income tax expense and earnings per diluted share.

 

The company also presents certain results on a constant currency basis, which compares results between periods as if foreign currency exchange rates had remained consistent period-over-period. Management monitors sales performance on an adjusted basis that eliminates the positive or negative effects that result from translating international sales into U.S. dollars. Management calculates constant currency by applying the foreign currency exchange rate for the prior period to the local currency results for the current period. Management believes that evaluating growth in net revenue on a constant currency basis provides an additional and meaningful assessment to both management and investors.

 

   
 

 

About Hillrom

 

Hillrom is a global medical technology leader whose 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Care™. Around the world, our innovations touch over 7 million patients each day. They help enable earlier diagnosis and treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication and shifting care closer to home. We make these outcomes possible through digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, advanced equipment for the surgical space and more, delivering actionable, real-time insights at the point of care. Learn more at hillrom.com.

 

Additional Information About the Merger and Where to Find It

 

This communication relates to the proposed transaction involving Hillrom. This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In connection with the proposed transaction, Hillrom filed with the U.S. Securities and Exchange Commission (the “SEC”) a definitive proxy statement on Schedule 14A (the “Proxy Statement”) on October 20, 2021. Hillrom commenced mailing the Proxy Statement and a proxy card to its shareholders on or about October 21, 2021. Hillrom has also filed and will file other materials with the SEC in connection with the proposed transaction. This communication is not a substitute for the Proxy Statement or any other document that Hillrom has filed or may file with the SEC or send to its shareholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, SHAREHOLDERS OF HILLROM ARE URGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders are able to obtain copies of the Proxy Statement and will be able to obtain other documents (when available) free of charge at the SEC’s website, www.sec.gov, or by visiting Hillrom’s investor relations website, https://ir.hill-rom.com/ir-home/default.aspx.

 

Participants in the Solicitation

 

Hillrom and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of Hillrom’s common stock in respect of the proposed transaction. Information about the directors and executive officers of Hillrom and their ownership of Hillrom’s common stock is set forth in the definitive proxy statement for Hillrom’s 2021 Annual Meeting of Stockholders, which was filed with the SEC on January 19, 2021, or its Annual Report on Form 10-K for the year ended September 30, 2020, and in other documents filed by Hillrom with the SEC. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the Proxy Statement and will be contained in other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available.

 

   
 

 

Forward-Looking Statements

 

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Statements concerning general economic conditions, our financial condition, results of operations, cash flows and business and our expectations or beliefs concerning future events, including the demand for our products, the ability to operate our manufacturing sites at full capacity, future supplies of raw materials for our operations, product launches, share repurchases, international market conditions, expectations regarding our liquidity, our capital spending, plans for future acquisitions and divestitures, and our operating plans; and any statements using phases such as we or our management “expects,” “anticipates,” “believes,” “estimates,” “intends,” “plans to,” “ought,” “could,” “will,” “should,” “likely,” “appears,” “projects,” “forecasts,” “outlook” or other similar words or phrases are forward-looking statements that involve certain factors, risks and uncertainties that could cause Hillrom’s actual results to differ materially from those anticipated. Such factors, risks and uncertainties include: (1) the future impact of the COVID-19 pandemic on Hillrom’s business, including but not limited to, the impact on its workforce, operations, supply chain, demand for products and services, and Hillrom’s financial results and condition; (2) Hillrom’s ability to successfully manage the challenges associated with the COVID-19 pandemic; (3) increasing regulatory focus on privacy and data security issues; (4) breaches or failures of Hillrom’s information technology systems or products, including by cyberattack, unauthorized access or theft; (5) failures with respect to compliance programs; (6) Hillrom’s ability to achieve expected synergies from acquisitions; (7) risks associated with integrating recent acquisitions; (8) global economic conditions; (9) demand for and delays in delivery of Hillrom’s products; (10) Hillrom’s ability to develop, commercialize and deploy new products; (11) changes in regulatory environments; (12) the effect of adverse publicity; (13) the impact of competitive products and pricing; (14) Hillrom’s ability to maintain or increase margins; (15) the potential loss of key distributors or key personnel; (16) the impact of the Affordable Health Care for America Act (including excise taxes on medical devices) and any applicable healthcare reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; (17) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement between the parties to the proposed transaction; (18) the failure to obtain the approval of Hillrom’s shareholders, (19) the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all; (20) risks related to disruption of management’s attention from Hillrom’s ongoing business operations due to the transaction; (21) the effect of the announcement of the transaction on the ability of Hillrom to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; (22) the ability to meet expectations regarding the timing and completion of the transaction; (23) uncertainty regarding actual or potential legal proceedings; (24) risks associated with transaction-related litigation; and (25) the other risks listed from time to time in Hillrom’s filings with the SEC. For additional information concerning factors that could cause actual results and events to differ materially from those projected herein, please refer to Hillrom’s Annual Report on Form 10-K for the year ended September 30, 2020, and in other documents filed by Hillrom with the SEC, including subsequent Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Hillrom is providing the information in this communication as of this date and assumes no obligation to update or revise the forward-looking statements in this communication because of new information, future events, or otherwise.

 

# # #

 

   
 

 

Hill-Rom Holdings, Inc. and Subsidiaries

Condensed Consolidated Statements of Income (Unaudited)

(In millions, except per share data)

 

   Three Months Ended
September 30
   Year Ended
September 30
 
   2021   2020   2021   2020 
Net Revenue                    
Product sales and service  $713.1   $   624.1   $   2,669.6   $   2,571.2 
Rental revenue   84.8    81.2    349.1    309.8 
Total net revenue   797.9    705.3    3,018.7    2,881.0 
                     
Cost of Net Revenue                    
Cost of goods sold   333.5    313.3    1,282.4    1,259.9 
Rental expenses   37.4    35.1    148.2    146.0 
Total cost of net revenue (excludes acquisition-related intangible asset
amortization)
   370.9    348.4    1,430.6    1,405.9 
                     
Research and development expenses   39.3    36.2    144.9    136.5 
Selling and administrative expenses   238.4    211.5    887.0    820.4 
Acquisition-related intangible asset amortization   27.9    27.7    108.6    109.0 
Special charges   7.3    15.3    47.4    41.5 
Operating Profit   114.1    66.2    400.2    367.7 
                     
Interest expense   (15.0)   (18.1)   (65.6)   (74.0)
Loss on extinguishment of debt           (9.8)   (15.6)
Investment income (expense) and other, net   (34.7)   3.5    (22.0)   (6.9)
                     
Income Before Income Taxes   64.4    51.6    302.8    271.2 
                     
Income tax expense   11.0    9.2    54.3    48.2 
                     
Net Income  $53.4   $42.4   $248.5   $223.0 
                     
Net Income per Basic Common Share  $0.81   $0.64   $3.75   $3.35 
                     
Net Income per Diluted Common Share  $0.80   $0.63   $3.72   $3.32 
                     
Average Basic Common Shares Outstanding (in thousands)   65,829    66,606    66,204    66,631 
                     
Average Diluted Common Shares Outstanding (in thousands)   66,663    67,181    66,847    67,212 

 

   
 

 

Hill-Rom Holdings, Inc. and Subsidiaries

Revenue Constant Currency (Unaudited)

(In millions)

 

                   U.S.   OUS 
   Three Months Ended
September 30
   Change As
Reported
   Constant
Currency
   Change As
Reported
   Change As
Reported
   Constant
Currency
 
   2021     2020                     
Net Revenue:                                   
Product sales and service  $713.1   $624.1    14.3%   13.6%   29.6%   (13.1)%   (14.9)%
Rental revenue   84.8    81.2    4.4%   4.2%   7.0%   (14.7)%   (16.8)%
Total net revenue  $797.9   $705.3    13.1%   12.5%   26.2%   (13.2)%   (15.0)%
                                    
Net Revenue:                                   
Patient Support Systems  $416.5   $365.0    14.1%   13.6%   27.4%   (19.2)%   (20.9)%
Front Line Care   296.2    260.0    13.9%   13.2%   21.3%   (3.6)%   (5.9)%
Surgical Solutions   85.2    80.3    6.1%   5.4%   46.1%   (15.4)%   (16.5)%
Total net revenue  $797.9   $705.3    13.1%   12.5%   26.2%   (13.2)%   (15.0)%
                                    
OUS - Outside of the United States                                   

 

                   U.S.   OUS 
   Year Ended
September 30
   Change As
Reported
   Constant
Currency
   Change As
Reported
   Change As
Reported
   Constant
Currency
 
     2021     2020                     
Net Revenue:                                   
Product sales and service  $2,669.6   $2,571.2    3.8%   1.9%   5.4%   0.8%   (4.8)%
Rental revenue   349.1    309.8    12.7%   11.9%   14.7%   (1.6)%   (8.1)%
Total net revenue  $3,018.7   $2,881.0    4.8%   3.0%   6.7%   0.7%   (4.9)%
                                    
Net Revenue:                                   
Patient Support Systems   1,568.3    1,539.1    1.9%   0.3%   2.5%   0.2%   (5.8)%
Front Line Care   1,117.0    1,025.0    9.0%   7.3%   11.1%   4.3%   (1.0)%
Surgical Solutions   333.4    316.9    5.2%   1.9%   19.6%   (4.2)%   (9.7)%
Total net revenue  $3,018.7   $2,881.0    4.8%   3.0%   6.7%   0.7%   (4.9)%
                                    
OUS - Outside of the United States                                   

 

   
 

 

Hill-Rom Holdings, Inc. and Subsidiaries

Reconciliation: Earnings Per Share (Unaudited)

(In millions, except per share data)

 

   Three Months Ended September 30, 2021   Three Months Ended September 30, 2020 
  

Operating

Margin

 

Income

Before

Income

Taxes

  

Income Tax

Expense

   Diluted
EPS
  

Operating

Margin

  

Income

Before

Income

Taxes

  

Income Tax

Expense

  

Diluted

EPS

 
As Reported   14.3%  $64.4   $11.0   $0.80    9.4%  $51.6   $9.2   $0.63 
Adjustments:                                        
Acquisition and integration costs and related fair value
adjustments
   6.1%   48.8    3.7    0.68    0.3%   2.0    0.4    0.03 
Acquisition-related intangible asset amortization   3.5%   27.9    6.7    0.31    3.9%   27.7    6.4    0.32 
Field corrective actions   %               0.4%   2.8    0.6    0.03 
Regulatory compliance costs   0.4%   2.6    0.6    0.03    0.4%   2.8    0.7    0.03 
Special charges   0.9%   7.3    1.3    0.09    2.2%   15.3    3.1    0.18 
(Gain) Loss on disposition of business   %               %   (2.9)   (0.3)   (0.04)
Pension settlement expense   %               %            
COVID-19 related costs and  benefits, net   (1.6)%   (11.5)   (0.7)   (0.16)   (0.1)%   (0.5)   (0.1)   (0.01)
LIFO Change   (0.9)%   (6.8)   (1.5)   (0.08)   %            
Adjusted Earnings   22.7%  $132.7   $21.1   $1.67    16.5%  $98.8   $20.0   $1.17 

 

   Year Ended September 30, 2021   Year Ended September 30, 2020 
  

Operating

Margin

 

Income

Before

Income

Taxes

  

Income Tax

Expense

   Diluted
EPS
  

Operating

Margin

  

Income

Before

Income

Taxes

  

Income Tax

Expense

  

Diluted

EPS

 
As Reported   13.3%  $302.8   $54.3   $3.72    12.8%  $271.2   $48.2   $3.32 
Adjustments:                                        
Acquisition and integration costs and related fair value
adjustments
   2.1%   62.7    6.9    0.84    %   (0.6)   1.8    (0.04)
Acquisition-related intangible asset amortization   3.6%   108.6    26.3    1.23    3.7%   109.0    26.1    1.23 
Field corrective actions   0.1%   1.6    0.4    0.02    0.2%   4.9    1.2    0.05 
Regulatory compliance costs   0.5%   15.1    3.7    0.17    0.5%   15.6    3.7    0.18 
Special charges   1.6%   47.4    11.0    0.54    1.4%   41.5    9.2    0.48 
Debt refinancing costs   %   9.8    2.3    0.11    %   16.1    3.7    0.18 
(Gain) Loss on disposition of business   %               %   (2.8)   (4.4)   0.02 
Pension settlement expense   %               %   8.4    1.9    0.10 
Litigation settlements   %   (6.8)   (1.6)   (0.08)   %   (1.2)   (0.3)   (0.01)
COVID-19 related costs and benefits, net   (0.4)%   (11.6)   (0.7)   (0.16)   0.2%   1.4    0.7    0.02 
LIFO Change   (0.2)%   (6.8)   (1.5)   (0.08)   %            
Adjusted Earnings   20.6%  $522.8   $101.1   $6.31    18.8%  $463.5   $91.8   $5.53 

 

   
 

 

Hill-Rom Holdings, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets (Unaudited)

(In millions, except share amounts)

 

   September 30,
2021
   September 30,
2020
 
ASSETS          
Current Assets          
Cash and cash equivalents  $271.8   $296.5 
Trade accounts receivable, net of allowances of $25.4 and $25.9 as of September 30, 2021 and 2020   671.2    594.9 
Inventories, net of reserves   319.4    352.0 
Other current assets   101.4    121.5 
Total current assets   1,363.8    1,364.9 
Property, plant and equipment   875.8    858.2 
Less accumulated depreciation   (587.7)   (552.1)
Property, plant and equipment, net   288.1    306.1 
Goodwill   2,221.7    1,835.5 
Other intangible assets and software, net   955.3    976.7 
Deferred income taxes   32.4    32.9 
Other assets   137.8    155.0 
Total Assets  $4,999.1   $4,671.1 
LIABILITIES          
Current Liabilities          
Trade accounts payable  $229.9   $236.5 
Short-term borrowings   235.7    222.3 
Accrued compensation   182.3    144.9 
Accrued product warranties   29.6    30.8 
Accrued rebates   50.7    44.8 
Deferred revenue   112.7    110.1 
Other current liabilities   150.3    162.8 
Total current liabilities   991.2    952.2 
           
Long-term debt   1,825.2    1,655.7 
Accrued pension and postretirement benefits   73.8    89.3 
Deferred income taxes   65.4    113.0 
Other long-term liabilities   163.8    134.8 
Total Liabilities   3,119.4    2,945.0 
SHAREHOLDERS' EQUITY          
Capital Stock:          
Preferred stock - without par value: Authorized - 1,000,000; none issued or outstanding          
Common stock - without par value: Authorized - 199,000,000   4.4    4.4 
Issued - 88,457,634 shares as of September 30, 2021 and September 30, 2020; Outstanding:
65,893,802 shares as of September 30, 2021 and 66,640,832 shares as of September 30, 2020
          
Additional paid-in capital   707.6    667.0 
Retained earnings   2,315.9    2,132.2 
Accumulated other comprehensive (loss)   (136.0)   (180.2)
Treasury stock, common shares at cost: 22,563,832 as of September 30, 2021 and 21,816,802 as of
September 30, 2020
   (1,012.2)   (897.3)
Total Shareholders’ Equity   1,879.7    1,726.1 
Total Liabilities and Shareholders' Equity  $4,999.1   $4,671.1 

 

   
 

 

Hill-Rom Holdings, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows (Unaudited)

(In millions)

 

   Year Ended September 30 
   2021   2020 
Operating Activities          
Net income  $248.5   $223.0 
Adjustments to reconcile net income to net cash, cash equivalents and restricted cash
provided by operating activities:
          
Depreciation and amortization of property, plant, equipment and software   77.2    69.8 
Acquisition-related intangible asset amortization   108.6    109.0 
Amortization of debt discounts and issuance costs   3.7    4.0 
Loss on extinguishment of debt   9.8    15.6 
Benefit for deferred income taxes   (32.0)   (19.0)
Loss on disposal of property, equipment, intangible assets and impairments   0.4    2.7 
Stock compensation   45.6    38.4 
Other operating activities   24.3    27.1 
Change in working capital excluding cash, current debt, acquisitions and dispositions:          
Trade accounts receivable   (67.6)   71.3 
Inventories   17.1    (91.8)
Other current assets   24.4    (14.8)
Trade accounts payable   1.9    24.0 
Accrued expenses and other liabilities   37.6    15.4 
Other assets and liabilities   (23.4)   7.0 
Net cash, cash equivalents and restricted cash provided by operating activities   476.1    481.7 
Investing Activities          
Purchases of property, plant, equipment and software   (92.1)   (105.9)
Proceeds on sale of property and equipment   2.4    2.5 
Payment for acquisition of businesses, net of cash acquired   (369.0)   (28.4)
Payments for acquisition of intangible assets   (30.0)    
Proceeds on sale of businesses       0.8 
Other investing activities   1.5    (0.2)
Net cash, cash equivalents and restricted cash used in investing activities   (487.2)   (131.2)
Financing Activities          
Payments of long-term debt   (50.1)   (50.1)
Borrowings on Revolving Credit Facility   870.0    190.0 
Payments on Revolving Credit Facility   (355.0)   (270.0)
Borrowings on Securitization Facility   60.6    17.7 
Payments on Securitization Facility   (47.2)   (45.5)
Borrowings on Note Securitization Facility   91.3    32.6 
Payments on Note Securitization Facility   (91.3)   (21.2)
Prepayment premium on redemption of 5.00% Notes and 5.75% Notes   (7.5)   (12.2)
Redemption of 5.00% Notes and 5.75% Notes   (300.0)   (425.0)
Cash dividends   (62.0)   (58.0)
Proceeds on exercise of stock options   10.5    8.6 
Stock repurchases for stock award withholding obligations   (9.5)   (16.5)
Stock repurchases in the open market   (130.7)   (54.1)
Other financing activities   7.5    8.7 
Net cash, cash equivalents and restricted cash used in financing activities   (13.4)   (695.0)
Effect of exchange rate changes on cash, cash equivalents and restricted cash   (0.2)   7.2 
Net Cash Flows   (24.7)   (337.3)
Cash, Cash Equivalents and Restricted Cash:          
At beginning of period   296.5    633.8 
At end of period  $271.8   $296.5 

 

 

 

 


The following information was filed by Hillrom Holdings, Inc. (HRC) on Friday, November 5, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Hillrom Holdings, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Hillrom Holdings, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word, Excel and CSV Downloads


Download Annual and Quarterly Reports as PDF, Word, Excel and CSV Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

See when company executives buy or sell their own stock


Insider Trading (Form 4)
Screenshot taken from Euronet (EEFT)
Last10K.com Member Feature

Use our calculated cost dollar values to discover when and how much registered owners BUY, SELL or excercise their company stock OPTIONS aggregated from Form 4 Insider Transactions SEC Filings

Continue

See how institutional managers trade a stock


Manager Portfolios (Form 13F)
Screenshot taken from General Motors (GM)
Last10K.com Member Feature

View which hedge funds, pension / retirement funds, endowments, banks and insurance companies have increased or decreased their positions in a particular stock. Includes Ownership Percent, Buy versus Sell comparison, Put-Call ratio and more.

Continue

Log in with your credentials

or    

Forgot your details?

Create Account